Cargando…

Treatment with Recombinant Factor XIII (Tretten) in a Pregnant Woman with Factor XIII Deficiency

Patient: Female, 37 Final Diagnosis: Factor XIII deficiency Symptoms: Bleeding • miscarriage Medication: — Clinical Procedure: — Specialty: Hematology OBJECTIVE: Rare disease BACKGROUND: Factor XIII deficiency is associated with recurrent miscarriages in women. CASE REPORT: In this report, we presen...

Descripción completa

Detalles Bibliográficos
Autor principal: Abdel-Samad, Nizar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5408647/
https://www.ncbi.nlm.nih.gov/pubmed/28432284
http://dx.doi.org/10.12659/AJCR.901502
Descripción
Sumario:Patient: Female, 37 Final Diagnosis: Factor XIII deficiency Symptoms: Bleeding • miscarriage Medication: — Clinical Procedure: — Specialty: Hematology OBJECTIVE: Rare disease BACKGROUND: Factor XIII deficiency is associated with recurrent miscarriages in women. CASE REPORT: In this report, we present a patient with factor XIII deficiency and some comorbidities who had had previous miscarriages. She began treatment with factor XIII subunit A (XIII-A) replacement treatment Recombinant factor XIII (Tretten) at a dose of 2500 units monthly and was able, for the first time, to carry a pregnancy almost to term. Although she experienced some obstetrical complications, she delivered a healthy baby. To the best of our knowledge, this is the first report of the use of Tretten during pregnancy. CONCLUSIONS: Tretten, which is not indicated in pregnancy, offered a safe, effective treatment for miscarriages secondary to factor XIII-A deficiency in our patient. Further research is required to confirm this finding.